Semax: The Nootropic Peptide for Cognitive Enhancement

Semax is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is a modified analog of the ACTH 4-10 fragment — a portion of adrenocorticotropic hormone that mediates the peptide's cognitive and neuroprotective effects without the adrenal-stimulating properties of full ACTH.

Semax has a decades-long study history in Russia, where it has been approved and used clinically for stroke rehabilitation and cognitive enhancement. Its primary mechanism — upregulation of BDNF (brain-derived neurotrophic factor) and enhancement of dopaminergic and serotonergic neurotransmission — positions it as one of the most mechanistically interesting nootropic peptides in the scientific literature.

What Is Semax?

Semax is a 7-amino acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro — derived from the ACTH 4-10 fragment with added Pro-Gly-Pro stabilization tail that significantly increases its stability and duration of action compared to native ACTH 4-10.

| Property | Value | |----------|-------| | Full sequence | Met-Glu-His-Phe-Pro-Gly-Pro | | Length | 7 amino acids (heptapeptide) | | Parent compound | ACTH 4-10 fragment | | Development | Russian Academy of Sciences, 1980s | | Primary applications | Cognitive enhancement, neuroprotection, stroke recovery | | Administration | Intranasal (most common); sublingual; SC injection | | Half-life | ~20 minutes (intranasal), longer with nasal mucosa absorption | | Clinical status | Approved in Russia for clinical use |

ACTH 4-10: The Parent Sequence

ACTH (adrenocorticotropic hormone) is a 39-amino acid peptide produced by the pituitary. Its primary known function is stimulating cortisol production from the adrenal gland — but study identified that the 4-10 amino acid segment (MEHFPGP) mediates distinct cognitive and neurotrophic effects independently of any adrenal action.

Semax retains the 4-10 fragment's cognitive properties but, critically, does not stimulate cortisol production because the adrenal-stimulating region of ACTH is elsewhere in the molecule. The added Pro-Gly-Pro tail increases enzymatic resistance and prolongs the peptide's activity.

Mechanism of Action

Semax produces its cognitive and neuroprotective effects through several complementary mechanisms.

1. BDNF Upregulation

The most extensively documented mechanism of Semax is its ability to rapidly upregulate brain-derived neurotrophic factor (BDNF) — the primary growth factor for neurons in the brain.

BDNF is essential for:

• Neuronal survival and maintenance
• Synaptic plasticity (the cellular basis of learning and memory)
• Hippocampal neurogenesis (formation of new neurons in the memory-forming region)
• Long-term potentiation (LTP) — the strengthening of synaptic connections with use

Studies in rodents has shown that Semax administration produces rapid and significant BDNF elevation in the hippocampus and cortex — regions most relevant to cognition and memory. This elevation appears within hours of administration and persists for days beyond the peptide's circulating half-life, suggesting lasting transcriptional changes.

2. NGF Expression

Semax also upregulates NGF (Nerve Growth Factor), a neurotrophin critical for:

• Peripheral nervous system maintenance
• Cholinergic neuron health (relevant to attention and memory)
• Neuronal plasticity in the basal forebrain

3. Dopaminergic System Enhancement

Studies has documented Semax's effects on dopamine neurotransmission:

• Increased dopamine receptor expression
• Enhanced dopaminergic neurotransmission in prefrontal cortex
• Effects consistent with improved working memory, focus, and executive function

The dopaminergic enhancement explains the acute stimulant-like quality that some Semax study subjects report — improved drive, motivation, and processing speed.

4. Serotonergic Modulation

Semax has also been shown to modulate serotonin pathways, with effects on:

• Serotonin receptor density
• Serotonergic neurotransmission in regions related to mood and stress response
• Possible anxiolytic secondary effects via serotonin system

5. Reduction of Neuroinflammation

Multiple studies have documented anti-inflammatory effects in the central nervous system:

• Reduced microglial activation
• Decreased pro-inflammatory cytokine production (IL-1β, TNF-α)
• These effects are particularly relevant in stroke and TBI study contexts

Key Studies Findings

Cognitive Enhancement

Russian clinical studies — conducted over decades — has documented cognitive improvements with Semax in:

• Working memory — improvements in digit span and working memory tasks
• Attention and focus — reduced error rates and improved sustained attention
• Processing speed — faster cognitive performance on standardized tests
• Learning and retention — improved acquisition and consolidation of new information

While much of this data comes from Russian-language publications and clinical settings, the mechanistic basis (BDNF upregulation, dopamine enhancement) is consistent with what would be predicted from the neuroscience literature.

Stroke Recovery and Neuroprotection

Semax is approved in Russia specifically for ischemic stroke rehabilitation. Studies findings include:

• Reduced neurological deficit scores when administered after experimental stroke in rodents
• Reduced infarct volume in animal models of ischemic stroke
• Accelerated functional recovery in behavioral tests after stroke
• The mechanism appears to involve BDNF/NGF upregulation, reduced neuroinflammation, and promotion of neuroplasticity

Optic Nerve Damage Studies

A unique area of Semax study involves optic nerve repair:

• Studies in animal models of optic nerve crush injury show Semax reduces retinal ganglion cell death
• NGF upregulation in the optic nerve pathway is the proposed mechanism
• Russian clinical studies have examined Semax for optic atrophy with reported improvements in visual acuity

ADHD-Related Studies

Some study has examined Semax's relevance to attention disorders, consistent with its dopaminergic effects. Its acute cognitive-enhancing and focus-supporting properties make it a subject of interest in this area, though clinical trial data in ADHD specifically is limited.

Dosing and Administration

Intranasal Administration

Intranasal delivery is the most common and most studied route for Semax. The nasal mucosa provides direct access to the olfactory bulb — an anatomical pathway for peptides to reach the brain more directly than through peripheral circulation.

| Parameter | Value | |-----------|-------| | Standard dose | 100–300 mcg per administration | | Frequency | 1–2x daily | | Timing | Morning; or morning and early afternoon | | Onset (acute effects) | 30–60 minutes | | Cumulative effects | Build over days to weeks of consistent use |

Note on nasal spray preparation: Semax nasal spray is typically prepared at a concentration of 1 mg/mL (1000 mcg/mL) in bacteriostatic water. Standard nasal spray actuators deliver approximately 0.1 mL per spray, providing 100 mcg per spray at this concentration.

Subcutaneous Injection

SC injection provides higher systemic bioavailability but bypasses the direct olfactory-bulb pathway that intranasal delivery offers. Some protocols use SC injection for systemic neuroprotection endpoints at doses of 100–300 mcg once or twice daily.

Sublingual Administration

Sublingual administration (under the tongue) offers better absorption than oral ingestion, though still less efficient than intranasal. Some scientists use this route when intranasal is impractical.

Onset and Duration

| Effect Type | Onset | Duration | |------------|-------|---------| | Acute cognitive (focus, clarity) | 30–60 minutes | 4–8 hours | | Cumulative (BDNF, neuroplasticity) | Days to weeks | Persists beyond dosing | | Post-cycle residual effects | After course | Days to weeks |

Cycling Recommendations

A common study approach cycles Semax in defined periods:

| Protocol | Duration | Off Period | Notes | |---------|---------|-----------|-------| | Short course | 2–3 weeks on | 2–3 weeks off | Acute cognitive boost study | | Standard cycle | 4–6 weeks on | 4 weeks off | BDNF/neuroplasticity study | | Extended protocol | 8–12 weeks on | 6–8 weeks off | Longer-term neuroprotection endpoints |

Semax vs. Selank: Comparison

Semax and Selank are the two most studied Russian nootropic peptides and are frequently compared and combined.

| Property | Semax | Selank | |----------|-------|--------| | Derivation | ACTH 4-10 analog | Tuftsin (immune peptide) analog | | Primary mechanism | BDNF upregulation, dopamine enhancement | GABA modulation, serotonin system | | Cognitive effect profile | Stimulating — focus, drive, processing speed | Calming — anxiety reduction, memory stabilization | | Anxiety impact | Neutral to mild anxiogenic at higher doses | Anxiolytic (reduces anxiety) | | Neuroprotection study | Strong (stroke, optic nerve) | Moderate | | Synergy together | Yes — stimulating + anxiolytic balance | Yes | | Best timing | Morning, early afternoon | Morning or afternoon | | Administration | Intranasal, SC | Intranasal, SC |

The combination of Semax and Selank is a well-established study approach — Semax provides the stimulating, BDNF-driven cognitive enhancement while Selank provides anxiolytic counterbalancing, smoothing the experience and adding complementary serotonin-system effects.

View Semax | View Selank

Storage and Handling

Lyophilized Semax:

• Refrigerate at 2–8°C; stable 18–24 months
• Freezer storage appropriate for long-term (up to 2 years)

Reconstituted Semax (nasal spray or injection):

• Bacteriostatic water for reconstitution
• Store at 2–8°C
• Use within 28–30 days
• Protect from light; store in amber vial if available

Studies Disclaimer

Important: All information in this guide is provided for educational and educational purposes only. Semax is not approved by the FDA for human therapeutic use in the United States. While it has clinical approval in Russia, it is sold in other jurisdictions as a study chemical for laboratory use only. This guide does not constitute medical advice. Always consult a licensed healthcare provider before considering any nootropic peptide protocol.